Defiance Connective Technologies ETF (NASDAQ: SIXG)

Ultime notizie per Defiance Connective Technologies ETF (NASDAQ:SIXG)

Defiance Connective Technologies ETF

Technology

Communication Services

Real Estate

The Fund uses a passive management (or indexing) approach to track the total return performance, before fees and expenses, of the Index. The Index is a rules-based index that consists of a tiered, modified market capitalization-weighted portfolio of the U.S.-listed equity securities, including depositary receipts, of companies whose products or services are predominantly tied to the development of 5G networking and communication technologies (collectively, 5G Companies).

Apple Inc

NVIDIA Corporation

Broadcom Corp - Common Cl A

Oracle Corp.

Ocisco Systems, Inc

Qualcomm Inc.

Advanced Micro Devices Inc.

Analog Devices, Inc.

Arista Networks Inc.

Nxp Semiconductors N V

Celestica, Inc.

Credo Technology Group Holding Ltd

Marvell Technology Inc

Kyndryl Hldgs Inc

Nokia Corp-spon ADR

Datadog Inc

Telefonaktiebolaget Lm Ericsson ADR

Psychedelics

Broad U.S. Equity ETFs

Markets

ETFs

AMZN

GOOGL

NERD

PLTR

PLTU

PSIL

RBLX

SIXG

TTWO

In un contesto di incertezza economica, alcuni fondi di investimento hanno dimostrato una notevole resilienza.

Turbolenze di mercato? No problem: 5 ETF che hanno guadagnato bene la scorsa settimana

Sixt SE

WIIM

CCLD

CareCloud shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 EPS guidance above estimates.

Barclays analyst David Anderson maintains Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) with a Overweight and lowers the price target from $50 to $48.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Tenaris, Lowers Price Target to $48

CTNT

Cheetah Net Supply Chain shares are trading lower after the company reported worse-than-expected Q1 EPS results.

Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) is looking for Q3 Adj EPS of $1.25-$1.75 vs $1.63 analyst estimate. sees sales of $715.000 million-$745.000 million vs $746.32 million analyst estimate.

Guidance

ATKR

Atkore Sees Q3 Adj EPS $1.25-$1.75 vs $1.63 Est; Sees Sales $715.000M-$745.000M vs $746.32M Est

STIM

Neuronetics shares are trading lower after the company reported a Q1 EPS miss.

BRCC

BRC shares are trading lower after the company reported a Q1 EPS miss.

Barclays analyst Maurice Patrick maintains Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYA#NASDAQ">LBTYA</a>) with a Equal-Weight and lowers the price target from $12 to $11.

LBTYA

Barclays Maintains Equal-Weight on Liberty Global, Lowers Price Target to $11

ATRA

Atara Biotherapeutics shares are trading higher after the company provided updates on EBVALLO and announced the FDA has lifted its clinical hold to resume the clinical trials.

i3 Verticals, Inc. ("i3 Verticals" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>), and Infinx, Inc. ("Infinx"), a leader in AI-powered revenue cycle management solutions, today announced the entry into a definitive agreement and the contemporaneous closing of the sale of i3 Verticals' Healthcare Revenue Cycle Management ("RCM") business, including its associated proprietary technology, to Infinx, in an all-cash transaction for $96 million, subject to post-closing purchase price adjustments.

IIIV

i3 Verticals Sells Healthcare RCM Business To Infinx In $96M All-Cash Deal

SIFY

Sify's Chennai And Noida Data Center AI Facilities Achieve NVIDIA DGX-Ready Certification

-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents
NEW YORK, May 6, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commercial CAR-T therapy at the University of Texas Southwestern Medical Center (UTSW) (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4420488-1&amp;h=3859462182&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06768905%3Fintr%3DIomab-ACT%26rank%3D1&amp;a=NCT06768905">NCT06768905</a>). Initial clinical data from this trial is expected in the second half of 2025. Actinium is developing Iomab-ACT as a targeted radiotherapy conditioning agent intended to replace non-targeted chemotherapeutic conditioning agents such as Fludarabine and Cyclophosphamide (Flu/Cy) to address serious CAR-T related toxicities including immune effector cell-associated neurotoxicity (ICANS) and cytokine release syndrome (CRS), to potentially improve patient access and outcomes. Currently, there are seven CAR-T therapies approved for certain leukemias and lymphomas and multiple myeloma, that over 150,000 patients are diagnosed with annually. &nbsp;In 2024, the seven approved CAR-T therapies generated over $4 billion in sales and CAR-T therapies are forecasted to reach $12 billion in annual sales in 2030.

Biotech

General

ATNM

Actinium Announces Enrollment Of First Patient In The Iomab-ACT Commercial CAR-T Trial At The University Of Texas Southwestern Medical Center; Initial Clinical Data Expected In The Second Half Of 2025

In a bold departure from prevailing economic forecasts, Cathie Wood, the CEO and CIO of ARK Investment Management, has asserted that the prolonged &#8220;rolling recession,&#8221; that has gripped the U.S. economy for the past three years is nearing an end, paving way for a productivity-led economic boom and a healthy, broader-based bull market.
What Happened: According to her latest newsletter, dated April 30, Wood argues that the aggressive monetary tightening by the Federal Reserve has sequentially affected various sectors of the economy, from housing and autos to manufacturing and small businesses.
Even the previously resilient high-end consumer and government sectors are now showing signs of weakening, with the Atlanta Fed&#8217;s GDPNow projecting a significant 2.5% annualized drop in real GDP for the first quarter.
Despite this widespread weakness and growing concerns of a recession extending into 2026 among many economists, Wood and ARK Investment Management hold a distinctly optimistic outlook.
They believe that as clarity emerges on tariff, tax, regulatory, and monetary policies within the next three to six months, the &#8220;stealth recession&#8221; will conclude.
&#8220;If the current tariff turmoil results in freer trade, as tariffs and non-tariff barriers come down in tandem with declines in other taxes, regulations, and interest rates, then real GDP growth and productivity should surprise on the high side of expectations at some point during the second half of this year,&#8221; stated her newsletter.
According to Wood, the three tailwinds for a bull market are;
<ul>
<li>Narrow Market Broadening: The current concentrated bull market is expected to widen.</li>
</ul>
<ul>
<li>Lower Interest Rates Ahead: The trend of rising interest rates is likely to reverse.</li>
</ul>
<ul>
<li>Innovation Valuation Reset: Premium valuations for innovation stocks have already significantly declined.</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45218040/warren-buffett-expresses-disappointment-over-dollar-depreciation-dont-want-to-own-assets-in-a-currency-that-is-really-going-to-hell">Warren Buffett Expresses Disappointment Over Dollar Depreciation: Don&#8217;t Want To Own Assets In A Currency That Is &#8216;Really Going To Hell&#8217;</a>
Why It Matters: The newsletter further added that &#8220;For those seeking to future-proof portfolios and participate in the potentially exponential upside of this technological revolution, we believe the opportunity is now.&#8221;
Wood further cautions against waiting for perfect clarity, suggesting that those who hesitate risk missing out on what could be the most transformative growth cycle in history.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Tuesday. The SPY was down 0.75% to $559.30, while the QQQ declined 1.01% to $481.00, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45214653/uber-could-win-the-robo-taxi-war-says-expert-analyst-predicts-75-gains-on-ride-hailing-cost-drop">Uber Could Win The &#8216;Robo Taxi War,&#8217; Says Expert: Analyst Predicts 75% Gains On Ride Hailing Cost Drop</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: ChrisStock82 / Shutterstock.com

Equities

Futures

Cathie Wood Bucks Consensus, Predicts Economic Boom And Broad Bull Market: 'The Opportunity Is Now'

UWM Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.06 by 300 percent. This is a 233.33 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $613.37 million which beat the analyst consensus estimate of $557.19 million by 10.08 percent. This is a 7.62 percent increase over sales of $569.96 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

UWMC

UWM Hldgs Q1 EPS $(0.12) Misses $0.06 Estimate, Sales $613.37M Beat $557.19M Estimate

EKSO

Ekso Bionics shares are trading lower after the company reported worse-than-expected Q1 financial results and HC Wainwright & Co. cut its price target on the stock from $9 to $4.

Barclays analyst Betty Jiang maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and lowers the price target from $37 to $35.

CTRA

Barclays Maintains Overweight on Coterra Energy, Lowers Price Target to $35

Baird analyst David Koning maintains Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) with a Outperform and raises the price target from $30 to $36.

Baird Maintains Outperform on Paymentus Holdings, Raises Price Target to $36

CaliberCos shares are trading higher after the company announced it entered into a development rights agreement for 15 new Hyatt studios in the US.

Barclays analyst Alex Scott maintains Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) with a Overweight and raises the price target from $36 to $38.

CRBG

Barclays Maintains Overweight on Corebridge Financial, Raises Price Target to $38

Baird analyst Tristan Gerra maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and lowers the price target from $42 to $34.

Baird Maintains Neutral on ON Semiconductor, Lowers Price Target to $34

PALI

Palisade Bio shares are trading lower after the company presented preclinical data for PALI-2108 as a colon-specific PDE4 inhibitor.

Press Releases

Defiance Announces Name and Ticker Symbol Change for FIVG to SIXG - Defiance Connective Technologies ETF

Defiance ETFs Announces Transition of QTUM and SIXG from NYSE Arca to Nasdaq

FIVG

QTUM

Comments

Defiance Connective Technologies ETF

Notizie

Ultime notizie per Defiance Connective Technologies ETF (NASDAQ:SIXG)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO